Members of both parties want the agency to stop copies of Lilly's unapproved obesity peptide from entering the US, per a post shared by Dr. TM Smith.
Recap by typeshit. Post by TM Smith, D.O. FAAEM on X.
Strive Specialties failed to revive its suit over GLP-1 competition. Novo still faces soft 2026 forecasts and an exploratory CagriSema analysis in women.
Reports say RFK Jr. backs an interim path for specialty compounding, while the FDA lists BPC-157 as a possible safety risk and doctors cite thin human evidence.
Belga reports the number of seized weight loss drugs in Belgium went up again, with officials concerned about an unofficial parallel market.
Clinics took about 60% of supply, and one Seoul clinic got more Mounjaro than 174 hospitals combined. The health ministry warns of sanctions and criminal referrals.
A hospital doctor walks through what these drugs do for weight management and diabetes care, and who might benefit from them.
A doctor-training account frames the experimental fat-reducing shot as a possible help against weight regain after GLP-1 treatment, which remains unproven.
Loading…